Chronic lymphocytic leukaemia trials in China

In China 48 Also abroad 308

48 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Where
Beijing, Guangzhou, Nanchang, Tianjin
Age
18 years and over
People
332 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05091424
Phase 4Taking people
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Where
Beijing, Changsha, Guangdong, Guangzhou, Lanzhou, Nanchang, Shanghai, Taizhou, Tianjin, Ürümqi, Xuzhou, Zhengzhou
Age
18 years and over
People
150 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07218341
Phase 1/2Not yet taking people in China
CAR-T Immunotherapy Targeting CD19- ALL
Where
Shenzhen
Age
6 months to 75 years
People
100
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT04016129
Phase 1Taking people
Phase Ib Clinical Study of Keynatinib
Where
Beijing, Chengdu, Shanghai
Age
18 years and over
People
75
Run by
Medolution Ltd.
See details and how to joinNCT04807881
Phase 1/2Taking people
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Where
Beijing, Guangzhou, Jinan, Tianjin, Zhengzhou
Age
18 years and over
People
408 worldwide
Run by
AstraZeneca
See details and how to joinNCT06564038 · EU 2024-515034-33-00
Phase 2Taking people
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Liuzhou, Nanchang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou
Age
18 years and over
People
490 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04728893 · EU 2023-504931-42-00
Phase 1/2Taking people
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Where
Beijing, Guangzhou, Suzhou
Age
18 years and over
People
258 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06697184 · EU 2024-518829-15-00
Phase 3Taking people
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Where
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hohhot, Jinan, Jining, Nanchang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shijiazhuang, Shiyan, Suzhou, Taizhou, Tianjin, Wuhan, Wuxi, Xiamen, Xi'an, Xinxiang, Yangzhou
Age
18 years and over
People
630 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06943872 · EU 2024-517131-52-00
Phase 1/2Taking people
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Where
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Qingdao, Shanghai, Suzhou, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Zhengzhou
Age
18 years and over
People
146
Run by
BeOne Medicines
See details and how to joinNCT05294731
Phase 1Taking people
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Where
Zhengzhou
Age
18 years and over
People
180 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT07424833
No phaseTaking people
Real-World Study of BCL-2 Inhibitor-Based Regimens in Chronic Lymphocytic Leukemia
Where
Nanjing
Age
18 years and over
People
300
Run by
The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07874451
Phase 3Taking people
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Hefei, Jinan, Liuzhou, Nanchang, Nanjing, Nanning, Suzhou, Taiyuan, Tianjin, Ürümqi, Wuhan, Xi'an, Xuzhou, Zhengzhou
Age
18 years and over
People
1,200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06136559 · EU 2022-501697-19-01
Phase 1/2Taking people
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Where
Beijing, Guangzhou, Shanghai, Tianjin, Wenzhou, Yichang, Zhengzhou
Age
18 years and over
People
689 worldwide
Run by
BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00
Phase 1/2Taking people
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Where
Hangzhou, Shanghai
Age
18 years and over
People
174 worldwide
Run by
AstraZeneca
See details and how to joinNCT06542250
Phase 3Taking people
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Where
Beijing, Binzhou, Changchun, Changsha, Chengdu, Dalian, Dazhou, Fuzhou, Guangzhou, Guiyang, Harbin, Jiangmen, Kunming, Lanzhou, Luzhou, Nanchang, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taian, Taiyuan, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xining, Xuchang, Xuzhou, Zhengzhou
Age
18 years and over
People
500 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06973187 · EU 2025-522860-34-00
Phase 3Taking people
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Where
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Tianjin, Xi'an, Zhengzhou
Age
18 years and over
People
500 worldwide
Run by
BeOne Medicines
See details and how to joinNCT07277231 · EU 2025-524366-21-00
Phase 2Not yet taking people in China
Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL
Where
Changsha, Guangzhou, Nanchang, Nanjing, Wuhan, Zhengzhou
Age
18 years and over
People
23
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07831395
No phaseEnrolling by invitation
Real-world Study of Acalabrutinib
Where
Shanghai
Age
18 years and over
People
160
Run by
Ruijin Hospital
See details and how to joinNCT06767891
Phase 1/2Taking people
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Where
Baoding, Bengbu, Chongqing, Guangzhou, Hangzhou, Hefei, Linyi, Nanchang, Shenyang, Suzhou, Tianjin, Zhengzhou
Age
12 years and over
People
160 worldwide
Run by
Sellas Life Sciences Group
See details and how to joinNCT04588922
Phase 3Taking people
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Where
Changsha, Guangzhou, Haikou, Hangzhou, Hefei, Nanchang, Nanning, Shanghai, Tianjin, Ürümqi, Wuhan, Yiwu
Age
18 years and over
People
737 worldwide
Run by
Loxo Oncology, Inc.
See details and how to joinNCT05254743 · EU 2023-507699-38-00
No phaseTaking people
Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases
Where
Shanghai
Age
18 years and over
People
1,500
Run by
Rong Tao
See details and how to joinNCT07727083
No phaseTaking people
Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients
Where
Hainan
Age
18 years to 75 years
People
30
Run by
Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
See details and how to joinNCT07763054
Phase 3Not yet taking people in China
A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Where
Nanjing, Zhengzhou
Age
18 years and over
People
128
Run by
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
See details and how to joinNCT07753369
Phase 2Taking people
A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL
Where
Nanjing
Age
18 years and over
People
75
Run by
Guangzhou Lupeng Pharmaceutical Company LTD.
See details and how to joinNCT07609823
Phase 1/2Taking people
A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
Where
Tianjin
Age
18 years and over
People
92
Run by
Guangzhou Lupeng Pharmaceutical Company LTD.
See details and how to joinNCT07609862